HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patients MUNICH,…
Month: June 2023
HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patients MUNICH,…
Grace Breeding Announces Brazil Field Test Results of its ProMagen™ (WDS Bio-Activator) in Soybean Plants Demonstrating Boosted Yields
– Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient…
Grace Breeding Announces Brazil Field Test Results of its ProMagen™ (WDS Bio-Activator) in Soybean Plants Demonstrating Boosted Yields
– Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient…
Appeal of Delisting Determination
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals…
Appeal of Delisting Determination
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals…
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corp. (NASDAQ: PDSB), a…
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corp. (NASDAQ: PDSB), a…
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation…
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation…
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary…
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary…
LifeMD Appoints William J. Febbo to its Board of Directors
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider…
LifeMD Appoints William J. Febbo to its Board of Directors
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider…
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT)…
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT)…
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy…
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy…
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) — ShapeTX, the programmable medicine company using AI and…
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) — ShapeTX, the programmable medicine company using AI and…